prostaglandin Inhibitors
2 drugsAbout prostaglandin
Prostaglandins are lipid signaling molecules involved in various physiological processes. They play crucial roles in inflammation, pain, and fever, and are synthesized from arachidonic acid by cyclooxygenase (COX) enzymes.
Prostaglandin pathways have long been therapeutic targets, though no genetic evidence currently links them to specific diseases. Modulating prostaglandin activity remains clinically relevant, as evidenced by approved drugs.
Two FDA-approved drugs, NEOPROFEN and ACULAR LS, target prostaglandin pathways, both are small molecules. These drugs are marketed by RECORDATI RARE and AbbVie, respectively, for other therapeutic areas.
Top prostaglandin Drugs
The competitive landscape includes RECORDATI RARE and AbbVie.
Low market concentration suggests opportunities for new entrants with differentiated prostaglandin-targeting drugs.
prostaglandin Drug Modality Landscape
Modalities
Routes of Administration
prostaglandin is druggable by small molecules, though no oral formulations are currently approved.
Consider exploring alternative modalities like biologics to differentiate from existing therapies.
prostaglandin Clinical Trials 357 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on prostaglandin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 48 | 36 | 9 | 3 | 80% |
| Phase 2 | 89 | 61 | 17 | 11 | 78% |
| Phase 3 | 76 | 50 | 13 | 12 | 79% |
| Phase 4 | 144 | 98 | 26 | 20 | 79% |
Top Sponsors
By Modality
prostaglandin Drug Approval Timeline (2003 - 2006)
The first drug was approved in 2003 and the most recent in 2006.
The limited approval span indicates potential saturation or challenges in developing new prostaglandin-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 246 (41 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on prostaglandin. A trial counts if an approved drug acting on prostaglandin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.